vitamin K antagonist (VKA), apixaban, rivaroxaban, and dabigatran. Despite being registered in Europe as a pharmaceutical against thromboembolic complications in AF patients, edoxaban was not obtainable in Poland. The APT group included ticagrelor, acetylsalicylic acid and/or clopidogrel, and prasugrel....